ASX:PTX Prescient Therapeutics (PTX) Stock Price, News & Analysis → This is a huge income gap many folks can’t fill right now (From DTI) (Ad) Free PTX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume537,831 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.88%Price TargetN/A Stock AnalysisStock Analysis Get Prescient Therapeutics alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Prescient Therapeutics Stock (ASX:PTX)Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.Read More Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. PTX Stock News HeadlinesMay 25, 2024 | msn.comPrescient ETF Adds New Securities to Its Income Provider Feeder FundMay 22, 2024 | msn.comPrescient Income Provider Feeder ETF Expands with New SecuritiesMay 20, 2024 | msn.comPrescient Expands Its Income Provider Feeder ETF PortfolioMay 18, 2024 | msn.comPrescient ETF Increases Securities with New ListingMay 18, 2024 | msn.comPrescient helps Reatile with equity injection to acquire a stake in Ursa EnergyMay 16, 2024 | investing.comPrescient Therapeutics Ltd (PTX)May 15, 2024 | msn.comPrescient Management Lists Additional PMXINC Securities on JSEApril 26, 2024 | msn.comPrescient Management Issues Over 114,000 New Securities in PMXINC ETFApril 18, 2024 | msn.comPrescient Management Expands Portfolio with Additional PMXINC Securities ListingApril 6, 2024 | msn.comPrescient Management Expands PIPETF Securities in the MarketApril 4, 2024 | msn.comPrescient ETF Expands Offering with Additional Securities ListingMarch 26, 2024 | msn.comPrescient ETF Expands with New Listings in Global Property PortfolioMarch 15, 2024 | msn.comPrescient ETF Expands with New Securities ListingMarch 6, 2024 | finance.yahoo.comWe're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash WiselyFebruary 1, 2024 | afr.comPrescient Therapeutics LimitedDecember 10, 2023 | au.investing.comPrescient Therapeutics’ PTX-100 Phase 1b study shows excellent safety and promising efficacy in T-cell lymphoma patientsNovember 20, 2023 | msn.comMoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunityNovember 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics nearing a potential payday with PTX-100: Pitt Street ResearchNovember 6, 2023 | au.investing.comPrescient Therapeutics to participate in prestigious conference; abstract online nowOctober 31, 2023 | msn.comCancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24October 17, 2023 | msn.comPrescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conferenceOctober 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics to present clinical data at prestigious US conferenceSeptember 19, 2023 | msn.comASX cancer stocks guide: Here’s everything you need to knowAugust 30, 2023 | msn.com‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fightingJune 16, 2023 | finance.yahoo.comPrescient Therapeutics showcases cell therapy data at prestigious ISCT conferenceSee More Headlines Receive PTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prescient Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PTX CUSIPN/A CIKN/A Webwww.ptxtherapeutics.com Phone61 3 9692 7222FaxN/AEmployees171Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,740,000.00 Net Margins-248.74% Pretax MarginN/A Return on Equity-32.67% Return on Assets-20.79% Debt Debt-to-Equity Ratio0.81 Current Ratio10.26 Quick Ratio17.31 Sales & Book Value Annual Sales$3.11 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.91 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares805,320,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.11 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Steven Lee Yatomi-ClarkeMD, CEO & DirectorUpaly BahadureDirector of Clinical Affairs & OperationsDr. Terrence G. Chew (Age 77)Chief Medical Officer Comp: $155.99kMs. Rebecca LimSenior Vice President of Scientific AffairsMs. Melanie Jaye Leydin B.Bus (Age 51)C.A., Company Secretary Comp: $158.4kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors PTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Prescient Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SkyCity Entertainment Group (SKC) and Findi (FND). This page (ASX:PTX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prescient Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Prescient Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.